Omron Healthcare India intends to Double its Revenue in the Next Three to Five Years

India Pharma Outlook Team | Wednesday, 30 August 2023

 India Pharma Outlook Team

Omron Healthcare India Pvt. Ltd., a subsidiary of Japanese company Omron Healthcare Co. Ltd., which is into the supply of home healthcare monitoring devices in India, is planning to double its revenue in 3 to 5 years, the company’s Managing Director Tetsuya Yamada said in an interview. He said India offered huge potential for growth considering the very low penetration levels and the demand for home monitoring devices, which would grow with more awareness on hypertension and heart-related diseases.

"Our revenue in India is only 3% of our total revenue." This 3% figure is also shared by Brazil. Consider the populations of Brazil (around 22 million) and India (140 million). "We now plan to double our sales in three to five years," he said. According to him, blood pressure monitors are currently used by 2% of the exposed population [people who have already been diagnosed with hypertension] in India, compared to 20% in Brazil, 35% in China, and 40% in Russia.

"So, you can imagine the potential for growth in India," Mr. Yamada said. He stated that the company would meet its goals simply by doubling its volume of business through increased awareness and distribution. While blood pressure monitors would be the company's primary focus, it would also continue to expand in the respiratory segment. It currently sells ten Japanese-imported products. Omron Healthcare Manufacturing India, another subsidiary of Japan's Omron Healthcare Co. Ltd., announced earlier this year that it would invest 128 crore in establishing a production unit in Chennai, Tamil Nadu.

This factory is set to begin production in 2025, beginning with blood pressure monitors. To broaden its offerings, the company intends to collaborate with healthcare service providers that specialise in remote health monitoring. It recently announced a collaboration with Bengaluru-based Tricog, a heart health AI company focusing on early diagnosis and management of heart disease in India, to enter the remote home heart monitoring and management segment. "We want to encourage home blood pressure monitoring." We intend to do the same with the ECG. It is still uncommon for people to perform ECGs at home. We also want to raise awareness about home ECG measurement in India. "We also want to expand distribution channel coverage so that we can be available everywhere," Mr. Yamada added.

© 2024 India Pharma Outlook. All Rights Reserved.